Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

N/A

4(50.0%)

Phase 1

4(50.0%)

8Total

N/A(4)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01555892Phase 1Recruiting

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Role: collaborator

NCT02291848Phase 1Recruiting

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Role: collaborator

NCT03192462Phase 1Completed

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

Role: collaborator

NCT05345080Not ApplicableUnknown

Houston "Breathe Easy" Healthy Homes-Based Model for Multifamily Rental Communities

Role: collaborator

NCT01068171Not ApplicableWithdrawn

Developing a Diabetic Foot Ulcer Protocol

Role: collaborator

NCT02253433Not ApplicableCompleted

The Houston HIITBAC for African Americans

Role: collaborator

NCT01437280Phase 1Withdrawn

GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers

Role: collaborator

NCT01419314Not ApplicableCompleted

Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy

Role: collaborator

All 8 trials loaded